- In April 2023, AbbVie Inc. announced promising real-world data for RINVOQ (upadacitinib), showcasing its effectiveness in maintaining clinical remission in patients with moderately to severely active ulcerative colitis. The findings, presented at the ECCO Congress, emphasized upadacitinib’s sustained benefits across diverse patient populations. This development highlights AbbVie's ongoing commitment to innovation in immunology and its strategic focus on expanding targeted therapies within the inflammatory bowel diseases market
- In March 2023, Takeda Pharmaceutical Company Limited launched an expanded access program for Entyvio subcutaneous (vedolizumab) in select countries, aimed at offering early access to patients with Crohn’s disease and ulcerative colitis ahead of broader commercial availability. This move reflects Takeda’s proactive approach to bridging therapeutic gaps and underscores its leadership in biologic treatments for IBD
- In March 2023, Eli Lilly and Company announced the Phase 3 trial initiation for mirikizumab in Crohn’s disease after receiving positive results from its ulcerative colitis studies. Mirikizumab is a monoclonal antibody targeting the IL-23 pathway, and its clinical progression signals Lilly’s growing presence in the IBD treatment landscape. This advancement represents the company's strategic effort to diversify its immunology portfolio
- In February 2023, Janssen Pharmaceuticals, a Johnson & Johnson company, secured regulatory approvals for STELARA (ustekinumab) label expansion in Europe, allowing its use in pediatric patients aged six and above with moderately to severely active ulcerative colitis. This development broadens treatment options for younger populations and reinforces Janssen’s role in delivering comprehensive IBD care solutions across all age groups
- In January 2023, Arena Pharmaceuticals, acquired by Pfizer, reported new findings from the Phase 2 CULTIVATE study evaluating etrasimod, an S1P receptor modulator, in patients with Crohn’s disease. The results demonstrated favorable safety and efficacy profiles, building anticipation for Phase 3 outcomes. This research milestone illustrates Pfizer's ambition to redefine oral treatment options and further solidify its footprint in the global IBD therapeutics market.
